Inovio Pharmaceuticals, Inc. (INO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.20. The rating moved from Neutral to Overbought on August 15, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$1.20
• Last changeMoved from Neutral to Overbought on August 15, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Inovio is a small, development‑stage biotech with a DNA vaccine/immunotherapy platform and a history of binary clinical catalysts. The company lacks sustainable commercial revenue and likely faces near‑term financing and execution risks, which makes the equity sensitive to trial news and market sentiment. Sector themes around biologics demand and biotech risk‑on flows could provide episodic upside, but underlying balance sheet constraints and competitive/regulatory hurdles keep the outlook uncertain. Investors should expect high volatility, potential dilution, and outcomes driven heavily by upcoming clinical readouts or partnership developments.

Key factors

• Early‑stage clinical pipeline centered on DNA vaccine/immunotherapy platform with periodic binary clinical readouts that can move the stock
• Historically limited or inconsistent revenue and dependence on partnerships/grants for non‑dilutive funding
• Balance sheet and cash‑runway constraints that increase probability of near‑term financing or dilution
• Management execution and prior operational setbacks have created execution risk but retained platform IP and technical expertise
• Broader sector flows into biotech/biologics and CDMO demand could provide a constructive sentiment tailwind for development‑stage names
• Low absolute share price and small‑cap profile yield higher volatility and sensitivity to news/social sentiment

Risks

• Clinical trial failures or disappointing interim/endpoint data leading to sharp share price declines
• Near‑term cash depletion requiring equity raises that dilute existing holders
• Regulatory setbacks or slower than expected approvals
• Competitive pressure from larger vaccine/oncology developers using more advanced or de‑risked modalities
• Manufacturing scale‑up challenges or unreliability of third‑party CDMOs for GMP supply
• Low trading liquidity and episodic social media driven volatility

Latest MarketMoodz coverage

• Hantavirus outbreak sparks pharma rally; Moderna leads gains2026-05-11

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.